Patents by Inventor Claus Crone Fuglsang
Claus Crone Fuglsang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160312201Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: July 11, 2016Publication date: October 27, 2016Applicant: NOVOZYMES A/SInventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Publication number: 20150099284Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: December 16, 2014Publication date: April 9, 2015Inventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Patent number: 8679774Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: GrantFiled: August 4, 2010Date of Patent: March 25, 2014Assignee: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Publication number: 20110171694Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicant: Novozymes A/SInventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Publication number: 20110110910Abstract: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: January 19, 2011Publication date: May 12, 2011Applicants: Novozymes A/S, Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Claus Crone Fuglsang, Peter Colin Gregory
-
Patent number: 7851176Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: GrantFiled: October 3, 2008Date of Patent: December 14, 2010Assignee: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Publication number: 20100291262Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: ApplicationFiled: August 4, 2010Publication date: November 18, 2010Applicant: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Publication number: 20100190681Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: April 12, 2010Publication date: July 29, 2010Applicant: NOVOZYMES A/SInventors: THOMAS THISTED, SOREN KJAERULFF, CARSTEN ANDERSEN, CLAUS CRONE FUGLSANG
-
Publication number: 20100135978Abstract: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: January 26, 2010Publication date: June 3, 2010Applicants: Novozymes A/S, Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Claus Crone Fuglsang, Peter Colin Gregory
-
Patent number: 7713723Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: GrantFiled: December 22, 2009Date of Patent: May 11, 2010Assignee: Novozymes A/SInventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Publication number: 20100099161Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: December 22, 2009Publication date: April 22, 2010Applicant: Novozymes A/SInventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Patent number: 7700338Abstract: The invention relates to isolated CGTases and isolated nucleic acid sequences encoding the CGTases. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the CGTases, in particular to cleaning and detergent composition comprising such CGTases.Type: GrantFiled: July 13, 2001Date of Patent: April 20, 2010Assignee: Novozymes A/SInventors: Per Lina Jorgensen, Claus Crone Fuglsang
-
Publication number: 20100022433Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: September 24, 2009Publication date: January 28, 2010Applicant: NOVOZYMES A/SInventors: THOMAS THISTED, SOREN KJAERULFF, CARSTEN ANDERSEN, CLAUS CRONE FUGLSANG
-
Patent number: 7632669Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: GrantFiled: December 6, 2007Date of Patent: December 15, 2009Assignee: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Publication number: 20090047384Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: ApplicationFiled: October 3, 2008Publication date: February 19, 2009Applicant: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Publication number: 20090029004Abstract: The present invention relates to phytase variants derived from a parent phytase which is homologous to a Peniophora lycii phytase and comprises at least one substitution in at least one of a number of positions corresponding to a position in the Peniophora lycii phytase. The variants are of improved properties, in particular of a higher specific activity and/or more thermostable than the parent phytase, e.g., of a Tm of up to 82° C. at pH 5.5, as determined by DSC, and/or of a doubted specific activity. The invention also relates to DNA encoding the phytase variants, methods of their production, as well as the use thereof, e.g., in animal feed and animal feed additives.Type: ApplicationFiled: May 25, 2007Publication date: January 29, 2009Applicant: Novozymes A/SInventors: Tomoko Matsui, Claus Crone Fuglsang, Allan Svendsen, Shiro Fukuyama
-
Publication number: 20080317726Abstract: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: June 16, 2006Publication date: December 25, 2008Applicants: Novozymes A/S, Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Claus Crone Fuglsang, Peter Colin Gregory
-
Publication number: 20080131951Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: ApplicationFiled: December 6, 2007Publication date: June 5, 2008Applicant: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schroder Glad, Gitte Budolfsen
-
Patent number: 7312062Abstract: The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.Type: GrantFiled: November 22, 2004Date of Patent: December 25, 2007Assignee: Novozymes A/SInventors: Kirsten Bojsen, Allan Svendsen, Claus Crone Fuglsang, Shamkant Anant Patkar, Kim Borch, Jesper Vind, Andreas Petri, Sanne O. Schrøder Glad, Gitte Budolfsen
-
Patent number: 7238378Abstract: The present invention relates to phytase variants derived from a parent phytase which is homologous to a Peniophora lycii phytase and comprises at least one substitution in at least one of a number of positions corresponding to a position in the Peniophora lycii phytase. The variants are of improved properties, in particular of a higher specific activity and/or more thermostable than the parent phytase, e.g. of a Tm of up to 82° C. at pH 5.5, as determined by DSC, and/or of a doubled specific activity. The invention also relates to DNA encoding the phytase variants, methods of their production, as well as the use thereof, e.g. in animal feed and animal feed additives.Type: GrantFiled: February 5, 2003Date of Patent: July 3, 2007Assignee: Novozymes A/SInventors: Tomoko Matsui, Claus Crone Fuglsang, Allan Svendsen, Shiro Fukuyama